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Purpose: To investigate the effect of eicosapentaenoic acid (EPA) on acute ocular inflammation in an animal model of
endotoxin-induced uveitis (EIU).
Methods: C57Bl/6 mice (6-week-old males) were orally treated with EPA at a dose of 50 mg/kg/day for 5 days. EIU was
then induced in the animals by intraperitoneal injection of 160 µg lipopolysaccharide (LPS). Twenty-four hours after LPS
injection, leukocyte adhesion to the retinal vasculature was evaluated by the concanavalin A lectin perfusion-labeling
technique, and leukocyte infiltration into the vitreous cavity was quantified. Furthermore, the protein levels of monocyte
chemotactic protein (MCP)-1, interleukin (IL)-6, intercellular adhesion molecule-1 and phospholyrated nuclear factor
(NF)-κB p65 in the retina and retinal pigment epithelium (RPE)–choroid complex were examined by enzyme-linked
immunosorbent assay (ELISA).
Results: At 24 h after LPS injection, the EIU animals treated with oral EPA administration showed a significant decrease
in leukocyte adhesion to the retinal vessels by 43.4% (p<0.01) and leukocyte infiltration into the vitreous cavity by 49.2%
(p<0.05). In addition, EPA significantly reduced the protein levels of MCP-1 and IL-6 in the retina and the RPE-choroid
complex. Furthermore, phosphorylation of NF-κB was suppressed by EPA treatment.
Conclusions: Our data suggest that EPA inhibits multiple inflammatory molecules in vivo. EPA may become a novel
strategy in the prevention and/or treatment of ocular inflammatory diseases.
Recent studies have elucidated that inflammation is one
of the characteristic features of systemic diseases such as
atherosclerosis, coronary heart disease, diabetes mellitus, and
hypertension [1-4]. Plasma levels of C-reactive protein and
pro-inflammatory cytokines, such as tumor necrosis factor
(TNF)-α and interleukin (IL)-6, are elevated in subjects with
essential  hypertension,  coronary  heart  disease  and  type  2
diabetes [5,6]. Furthermore, evidence is emerging that anti-
inflammatory drugs ameliorate the conditions and/or delay the
onset of these systemic diseases [7-9]. Consequently, it seems
likely  that  prevention  and/or  suppression  of  systemic
inflammation  reduces  the  risks  of  these  life-threatening
diseases, and thus to that end much attention has been paid to
a variety of types of candidate anti-inflammatory agents. One
such promising type is that of the safe disease-modifying
nutrients, which can be ingested over a long period without
remarkable  harm.  For  example,  clinical  studies  have
demonstrated that administering higher doses per bodyweight
of  fish  oil  beneficially  modulated  systemic  inflammatory
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processes [10-12]. Moreover, epidemiological observations
have revealed that the Inuit, who consume fish daily, have a
lower  incidence  of  autoimmune  and/or  inflammatory
disorders compared with gender- and age-matched groups
living in Denmark [13]. As a result of these investigations,
fish  oil  has  become  recognized  as  an  important  dietary
supplement for prevention of systemic diseases caused by
underlying inflammatory responses.
Eicosapentaenoic acid (EPA) is one representative of the
ω-3 polyunsaturated fatty acids (PUFA), which are highly
contained in fish oil. EPA has been clinically used in patients
with hyperlipidemia to lower serum lipid levels, and it has
been shown to produce anti-inflammatory effects [14,15],
which,  taken  together,  suggest  that  the  preventive  or
protective effects of fish oil in systemic diseases are, at least
in part, attributed to EPA. It was shown, for instance, that
EPA-rich fish oil ameliorates systemic human inflammatory
diseases such as rheumatoid arthritis [16]. Similarly, EPA
reduced  the  recurrence  of  aphtha  in  patients  with  Behçet
disease, a cause also of uveitis [17]. In accordance with the
clinical data, EPA decreased leukocyte chemotaxis, adhesion
molecule  expression,  and  production  of  pro-inflammatory
cytokines in an animal model of systemic diseases [18,19].
Our  group  has  also  elucidated  that  EPA  suppresses  the
formation of inflammation-induced neovascularization and
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1382choroidal  neovascularization  via  suppression  of  pro-
inflammatory  cytokines  [20].  Thus,  accumulating  data
propose a protective benefit of EPA in ocular inflammatory
diseases.  However,  despite  the  documented  anti-
inflammatory effects of EPA, the molecular mechanism(s) by
which EPA modulates acute ocular inflammation is not well
understood. In this study, we investigate EPA’s effects on
ocular inflammation, using an established animal model, the
endotoxin-induced uveitis (EIU) [21].
METHODS
Endotoxin-induced uveitis and EPA treatment: Six-week-old
C57Bl/6 mice (CLEA, Tokyo, Japan) were used. Animals
were orally fed with either EPA (kindly given by the Mochida
Pharmaceutical, Tokyo, Japan) at a dose of 50 mg/kg/day or
vehicle  solution  (CMC:  carboxymethylcellulose)  using
stomach  sonde  for  5  days,  and  then  received  a  single
intraperitoneal injection of 160 μg lipopolysaccharide (LPS)
from  Escherichia  coli  (Sigma-Aldrich,  St.  Louis,  MO)  in
phosphate buffered saline (PBS). Control animals received
intraperitoneal  injections  of  the  same  volume  of  vehicle
(300 µl of PBS). All animal experiments were approved by
the Animal Care Committee of the Keio University School of
Medicine  and  conducted  in  accordance  with  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Quantification  of  firm  leukocyte  adhesion:  Mice  were
anesthetized  with  intramuscular  injection  of  a  mixture  of
80 mg/kg Ketamine and 16 mg/kg Xylazine before surgical
procedures.  Leukocytes  firmly  adhering  to  the  retinal
vasculature  were  visualized  and  quantified  by  perfusion-
labeling  with  fluorescein-isothiocyanate  (FITC)-coupled
concanavalin A lectin (Con A; Vector, Burlingame, CA), as
described  previously  [22].  Briefly,  the  chest  cavity  was
opened under deep anesthesia and a 27-gauge cannula was
introduced into the left ventricle. Animals were perfused with
2  ml  of  PBS  to  remove  intravascular  content,  including
nonadherent leukocytes. Perfusion with Con A (2 ml) was
then  performed  to  label  adherent  leukocytes  and  vascular
endothelial cells, followed by removal of residual unbound
lectin with 2 ml of PBS perfusion. Afterwards, eyes were
enucleated and retinas were flatmounted. Flatmounted retinas
were  imaged  with  an  epifluorescence  microscope  (IX71;
Olympus, Tokyo, Japan), and the total number of Con A-
stained leukocytes per retina was counted in a masked fashion.
Analysis  of  leukocyte  infiltration  into  the  vitreous  cavity:
Leukocyte infiltration into the vitreous cavity was analyzed,
as described previously [22]. Briefly, 24 h after LPS injection,
eyes  were  enucleated  from  the  animals  while  under  deep
anesthesia and fixed in 4% PFA. Three 5 µm paraffin sections
were prepared at a distance of 100 µm from each other with
the middle section passing through the optic nerve. In the
sections, the number of infiltrating cells in the vitreous cavity
was  counted  and  the  averaged  numbers  were  used  for
evaluation.
Enzyme-linked immunosorbent  assay  (ELISA): The  retinal
tissue and retinal pigment epithelium (RPE)-choroid complex
of each mouse were carefully isolated and placed into 100 µl
of  lysis  buffer  (0.02M  HEPES,  10%  glycerol,  10  mM
Na4P2O7, 100 μM Na3VO4, 1% Triton, 100 mM NaF, and
4 mM EDTA [pH 8.0]) supplemented with protease inhibitors.
After the sonication, the lysate was centrifuged at 20,400× g
for 15 min at 4 °C. The protein levels of monocyte chemotactic
protein (MCP)-1, IL-6, and intercellular adhesion molecule
(ICAM)-1 in the supernatant were determined with mouse
MCP-1,  IL-6,  and  ICAM-1  ELISA  kits  (R&D  Systems,
Minneapolis, MN).
The level of phosphorylated nuclear factor (NF)-κB p65
in the supernatant was also determined with the mouse pNF-
κB p65 Sandwich ELISA kit (Cell Signaling, Danvers, MA),
according to the manufacturer’s protocols. The tissue sample
concentration  was  calculated  from  a  standard  curve  and
corrected for protein concentration.
Statistics: All results are expressed as mean±SEM (standard
error) with n-numbers as indicated. Student’s t test was used
for statistical comparison between the groups. Differences
were considered statistically significant at p<0.05.
RESULTS
Impact of EPA on the leukocyte recruitment cascade during
ocular inflammation: To study the effects of EPA on acute
ocular  inflammation,  first  we  counted  the  number  of
leukocytes adhering to the vessels in the retinal flatmounts of
EIU animals with or without EPA treatment. Control animals
without LPS stimulation showed no or very few adhering
leukocytes in the retinal vessels (8±4 cells/retina, n=9; Figure
1A,B). However, at 24 h after LPS injection, a large number
of leukocytes firmly adhered to the retinal vessels in vehicle-
treated  animals  (182±42  cells/retina,  n=14;  Figure  1A,B)
compared to controls. By contrast, the EIU animals treated
previously with oral EPA administration over a 5-day period
showed a significant decrease in leukocyte adhesion to the
retinal vessels by 43.4% (103±31 cells, n=16, p<0.01, Figure
1A,B) compared with the vehicle-treated EIU animals.
Next, to study the impact of EPA on leukocyte infiltration
into  the  vitreous  cavity,  we  quantified  the  number  of
leukocytes  in  the  vitreous  of  control  versus  EIU  animals
treated with either EPA or vehicle solution. Representative
sections from EIU animals showed extravasated leukocytes
around the optic disc (Figure 2A), while very few leukocytes
were found in the vitreous cavity of normal animals (data not
shown),  as  described  previously  [22].  Specifically  and
moreover, upon counting we confirmed a higher number of
leukocytes to be in the vitreous of these EIU animals with
vehicle-only treatment (19±2 cells/section, n=8; Figure 2B).
However, compared to this group of animals, the number of
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1383infiltrating cells into the vitreous cavity of the EIU animals
having undergone EPA treatment was significantly reduced
by 49.2% (10±2 cells/section, n=8, p<0.05; Figure 2B).
Impact  of  EPA  on  expression  of  inflammation-associated
molecules  in  the  retina:  To  further  determine  whether
supplemental  EPA  may  ameliorate  ocular  inflammatory
responses  during  EIU,  we  also  measured  representative
inflammation-associated molecules, i.e., MCP-1, IL-6, and
ICAM-1, in the retina. The level of MCP-1 was undetectable
Figure 1. Impact of EPA on firm leukocyte adhesion in the retinal
vessels during EIU. A: Representative micrographs of flatmounted
retinas from normal control mice (a,b), vehicle-treated EIU mice
(c,d) and EPA-treated (50 mg/kg BW) EIU mice (e,f) at 24 h after
treatment  and  EIU-induction.  Firmly  adhering  leukocytes  in  the
retinal vasculature were visualized by perfusion with ConA. Arrows
indicate  firmly  adhering  leukocytes  in  the  inflamed  retinal
vasculature (c-e). Scale bars=100 µm. B: Quantification of firm
adhering leukocytes in the retinal vessels. Values are means±SEM
(n=9 to 16). †p<0.01.
in the retinal tissue of control animals (n=7; Figure 3A). In the
EPA-treated animals, retinal MCP-1 (76.6±23.6 pg/mg total
protein, n=7) was significantly decreased by 48.2% at 24 h
after  LPS  injection,  compared  to  the  vehicle-treated  EIU
animals (148±10.2 pg/mg, n=6, p<0.05; Figure 3A). Similar
to MCP-1, the level of IL-6 protein was also undetectable in
the retinal tissue of control animals (n=6; Figure 3B). Whereas
EIU animals showed the upregulation of IL-6 in the retina
(1.5±0.4 pg/mg, n=6), EPA treatment significantly reduced
the  average  level  of  retinal  IL-6  (0.08±0.07  pg/mg,  n=6,
p<0.05; Figure 3B) by 94.5% at 24 h after LPS injection.
In  contrast,  protein  levels  of  ICAM-1  were  not
significantly  statistically  different  between  vehicle-treated
EIU animals (18.6±2.6 ng/mg, n=6) and EPA-treated EIU
animals (15.8±1.4 ng/mg, n=5, p=0.378; Figure 3C).
Impact  of  EPA  on  expression  of  inflammation-associated
molecules  in  the  RPE-choroid  complex:  To  investigate
whether  supplemental  EPA  may  suppress  inflammatory
molecules  in  the  uveal  tissue  during  EIU,  we  measured
MCP-1,  IL-6,  and  ICAM-1  in  the  RPE-choroid  complex.
Twenty-four hours after LPS-injection, the average level of
MCP-1 in the RPE-choroid complex of the EIU animals was
upregulated (519.0±57.3 pg/mg, n=8, p<0.01) compared with
that of the controls (8.6±2 pg/mg, n=4; Figure 4A). In contrast,
protein levels of MCP-1 in the RPE-choroid complex were
significantly decreased by 31.9% in the EPA-treated animals
(353.3±36.2 pg/mg, n=8, p<0.05; Figure 4A). As for IL-6 in
the RPE-choroid complex, EPA-treated EIU animals showed
a decrease in the average level (9.9±1.4 pg/mg, n=8) by 73.9%
in  comparison  with  EIU  animals  (38.0±4.5  pg/mg,  n=8,
p<0.01; Figure 4B). Similar to the retinal tissue, the level of
IL-6 was undetectable in the RPE-choroid complex of control
animals (Figure 4B).
The  protein  levels  of  ICAM-1  were  not  significantly
statistically  different  between  vehicle-treated  EIU  animals
(106.9±4.2  ng/mg,  n=8)  and  EPA-treated  EIU  animals
(103.3±2.9 ng/mg, n=8, p=0.477; Figure 4C).
Impact of EPA on suppression of NF-κB activation: To further
explore  the  mechanism  by  which  EPA  suppressed  acute
ocular  inflammation,  we  examined  NF-κB  activation  by
measuring the pNF-κB p65 protein level in the retina and the
RPE-choroid  complex  (Figure  5).  As  a  preliminary
experiment,  we  first  sought  the  time  course  of
phosphorylation of the NF-κB p65 protein during EIU. After
LPS stimulation, the pNF-κB p65 level increased, peaked at
1.5  h,  and  reached  a  plateau  in  the  retina  (Figure  5A).
Likewise,  in  the  RPE-choroid  complex,  the  pNF-κB  p65
protein level peaked at 1.5 h; however, unlike in the retina it
returned to the base value at 24 h after LPS injection (Figure
5C). The data indicated that the time point to evaluate EPA-
treatment on NF-κB activation was 1.5 h after LPS injection.
At 1.5 h after LPS injection, retinal NF-κB activation was
significantly  increased  in  vehicle-treated  EIU  animals
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5B).  However,  EPA  administration  reduced  the
phosphorylation of NF-κB p65 protein by 34.5% in the retinal
tissues of EIU animals (n=10, p<0.05; Figure 5B). In the RPE-
choroid complex, EPA administration decreased the pNF-κB
p65 protein by 27.1% compared with EIU animals (n=4 to 10,
p<0.05; Figure 5D).
DISCUSSION
In the current study, we describe the therapeutic effect of EPA
on  acute  ocular  inflammation  using  an  animal  model  of
experimental uveitis. EPA suppresses the expression of pro-
inflammatory cytokines and reduces the level of pNF-κB p65
in the posterior segment of the eye. To our knowledge, this is
the first report of in vivo evidence regarding the protective
Figure  2.  Impact  of  EPA  on
inflammatory leukocyte infiltration into
the vitreous cavity. A: Representative
micrographs  of  leukocyte  infiltration
into the vitreous of EIU mice with or
without  EPA  administration.  Arrows
indicate the infiltrated leukocytes in the
vitreous. B: Quantification of infiltrated
leukocytes in the vitreous cavity of EIU
animals  treated  with  or  without  EPA
administration. Values are means±SEM
(n=8). *p<0.05.
Figure 3. Role of EPA on expression of inflammatory mediators and endothelial adhesion molecules in the retina during EIU. Protein levels
of MCP-1 (A), IL-6 (B), and ICAM-1 (C) in the retina from vehicle-treated normal control mice, vehicle-treated EIU mice, and EPA-treated
EIU mice were measured by ELISA at 24 h after the treatment. Values are means±SEM (n=5 to 7). *p<0.05.
Figure 4. Role of EPA on expression of inflammatory mediators and endothelial adhesion molecules in the RPE-choroid complex during EIU.
Protein levels of MCP-1 (A), IL-6 (B), and ICAM-1 (C) in the RPE-choroid complex from vehicle-treated normal control mice, vehicle-
treated EIU mice and EPA-treated EIU mice were measured by ELISA at 24 h after the treatment. Values are means±SEM (n=4 to 8). †p<0.01.
*p<0.05.
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1385effect  of  ω-3  PUFA  during  acute  retinal  and  choroidal
inflammation.
It  has  been  reported  that  leukocytes  are  markedly
attracted to inflamed ocular tissues such as the iris [23,24],
vitreous cavity [22,25], and retina [26,27] in the EIU model.
Consistent with the previous studies, we showed that LPS-
induced acute inflammation caused the increase of leukocyte
recruitment into the eye. In the current study, EPA treatment
reduced the accumulation of adherent leukocytes to the retinal
vessels by 43.4% and infiltrated leukocytes into the vitreous
cavity  by  49.2%,  suggesting  that  EPA  suppresses  the
leukocyte  recruitment  cascade,  at  least,  earlier  than  the
adhesion step. Previously, it was reported that EPA decreased
neutrophil infiltration in an animal model of contact dermatitis
[28]  and  neutrophil  transmigration  through  cultured
endothelial  cells  [29].  In  addition,  EPA  significantly
attenuated macrophage infiltration into inflamed pancreatic
parenchyma  in  a  model  of  experimental  acute  edematous
pancreatitis  [30].  Neutrophils  and  macrophages  are  major
leukocyte constituents recruited into the ocular tissues during
EIU [21,31]. Therefore, previous and present data indicate the
potential of EPA as a therapeutic strategy against uveitis via
blockade of the leukocyte recruitment cascade.
The anti-inflammatory aspects of ω-3 PUFAs are also
related to the regulation of inflammatory cytokines [32]. In
the  current  study,  we  investigated  the  impact  of  EPA
supplementation on the production levels of selected members
of  these  inflammation-associated  molecules  during
experimental  ocular  inflammation.  Our  data  showed  that
systemic administration of EPA significantly decreased the
protein  levels  of  the  pro-inflammatory  cytokine  IL-6  and
potent  macrophage-recruiting  chemokine  MCP-1  in  the
inflamed retinas and RPE-choroid complexes. IL-6 plays a
key  role  in  the  pathogenesis  of  EIU,  in  concert  with
inflammatory cytokines TNF-α and IL-1β [33-35]. MCP-1 is
an important mediator of monocyte infiltration [36], which is
upregulated  during  EIU  [35,37,38].  It  was  previously
documented  that  infiltrated  leukocytes  were  the  cellular
source of IL-6 [34] and MCP-1 [38] in ocular tissues. Thus,
attenuation of leukocyte recruitment by EPA may result in the
decreased production levels of IL-6 and MCP-1 in the retina
and choroid.
Interestingly,  in  this  study  the  level  of  the  ICAM-1
protein,  an  endothelial  adhesion  molecule  regulating
leukocyte  recruitment,  was  not  decreased  by  EPA  in  the
inflamed ocular tissues. The protein level of retinal ICAM-1
in EPA-treated EIU animals did show a trend to lower levels
compared  with  vehicle-treated  EIU  animals,  however  the
difference  did  not  reach  statistical  significance.  During
inflammation  leukocytes  are  recruited  in  a  cascade-like
fashion, starting with rolling, followed by firm adhesion and
extravasation. In addition, ICAM-1 is known to be a key
molecule upregulated in the pathogenesis of EIU [22,35].
Thus, previous reports demonstrated the reduction of ICAM-1
expression by therapeutic intervention, and it was concluded
in the studies that this reduction resulted in attenuation of
leukocyte  adhesion  and/or  transmigration  [35,39].  By
contrast,  the  current  data  suggest  that  EPA  affects  the
leukocyte recruitment by a different pathway. In fact, Tull et
al.  showed  that  EPA  had  no  ability  to  decrease  adhesion
molecules such as E-selectin and ICAM-1, representatives of
endothelial  surface  adhesion  molecules,  in  cultured
endothelial cells stimulated with TNF-α, yet EPA reduced the
neutrophil transmigration in their study [29]. Instead, they
demonstrated that EPA reduced CD11b on the surface of
neutrophils [29]. CD11b is a component of the leukocyte
adhesion  molecule  Mac-1  (CD11b/CD18),  which  is  a  β2
integrin family member that binds to ICAM-1 and is expressed
on the surface of neutrophils and macrophages [40,41]. This
indicates that EPA may reduce the leukocyte recruitment by
Figure 5. Impact of EPA on pNF-κB in
the  retina  and  RPE-choroid  complex
after LPS injection. A: Time course of
pNF-κB p65 in the Retina. Values are
means±SEM (n=6 at each time point).
B: Bars represent the protein level of
pNF-κB p65 in retinal tissue, 1.5 h after
LPS injection. Values are means±SEM
(n=4 to 10). C: Time course of pNF-κB
p65  in  the  RPE-choroid  complex.
Values are means±SEM (n=6 at each
time  point).  D:  Bars  represent  the
protein level of pNF-κB p65 in the RPE-
choroid  complex,  1.5  h  after  LPS
injection. Values are means±SEM (n=4
to 10). †p<0.01 and *p<0.05.
Molecular Vision 2010; 16:1382-1388 <http://www.molvis.org/molvis/v16/a152> © 2010 Molecular Vision
1386targeting  leukocyte  surface  adhesion  molecules,  but  not
endothelial surface adhesion molecules. It will be important
to explore the effect of EPA on endothelial and leukocyte
surface adhesion molecules in vivo, e.g., in the EIU model.
We  demonstrated  that  the  level  of  pNF-κB  p65  was
significantly suppressed by EPA in the inflamed retina and
choroid. LPS downstream signaling leads to the activation of
NF-κB [42]. NF-κB regulates various inflammatory processes
[43], including transcription of the IL-6 [44] and MCP-1 genes
[45,46].  Recent  studies  have  shown  that  ω-3  PUFA
downregulates the activity of NF-κB [47]. Therefore, in this
study  it  seems  that  EPA  decreases  the  secretion  of
inflammatory factors such as IL-6 and MCP-1 via suppression
of NF-κB activation.
In summary, we show that systemic treatment of EPA
effectively suppresses acute ocular inflammation in the EIU
model. Specifically EPA reduces leukocyte recruitment to the
vitreous cavity and retina during acute ocular inflammation.
The attenuation of leukocyte recruitment might lead to the
reduction of secretion of IL-6 and MCP-1. In addition, EPA
also suppressed NF-κB activation, which regulates IL-6 and
MCP-1  transcription.  Thus,  it  may  be  that  EPA  has  a
reciprocal pathway to decrease the levels of pro-inflammatory
cytokines via regulation of NF-κB activation and leukocyte
recruitment. Our data suggest EPA, a constituent of fish oil,
may be beneficial in the prevention and treatment of uveitis.
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